A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: The VIA study

British Journal of Ophthalmology

Volumn 94, Issue 2, 2010, Pages 174-179

  Potter, M J ^a   Claudio, C C ^a   Szabo, S M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VERTEPORFIN;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; LENS DISEASE; MALE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RETINA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA TEAR; SHAM PROCEDURE; STROKE; THICKNESS; TRANSIENT ISCHEMIC ATTACK; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 76149141821     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.155531     Document Type: Article

References (22)

1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
3. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5.
4. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
5. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
6. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90.
7. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-42.
8. Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145:862-74.
9. Schmidt-Erfurth U, Wolf S, PROTECT Study Group. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 2008;92: 1628-35.
10. Kiss CG, Simader C, Michels S, et al. Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study. Br J Ophthalmol 2008;92:1620-7.
11. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-85.
12. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-40.
13. Dhalla MS, Shah GK, Blinder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988-93.
14. Aggio FB, Melo GB, Hofling-Lima AL, et al. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. Acta Ophthalmol Scand 2006;84:831-3.
15. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007;245:1273-80.
16. Ladewig MS, Karl SE, Hamelmann V, et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2008;246:17-25.
17. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in agerelated macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-57.
18. Sacu S, Varga A, Michels S, et al. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study. Br J Ophthalmol 2008;92:1347-51.
19. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1161-73.
20. Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trialsdTAP report 1. Arch Ophthalmol 1999;117:1329-45.
21. Krebs I, Binder S, Stolba U, et al. Optical coherence tomography guided retreatment of photodynamic therapy. Br J Ophthalmol 2005;89:1184-7.
22. van Velthoven ME, de Smet MD, Schlingemann RO, et al. Added value of OCT in evaluating the presence of leakage in patients with age-related macular degeneration treated with PDT. Graefes Arch Clin Exp Ophthalmol 2006;244:1119-23.